|
| 瑞舒伐他汀治疗不稳定型心绞痛疗效及对血脂、血浆金属蛋白酶的影响 |
| The Effect of Rosuvastatin Tablets on the Plasma Levels of Lipid and Etalloprotease in the Treatment of Patients with Unstable Anginapectoris |
| |
| DOI： |
| 中文关键词: 不稳定型心绞痛 瑞舒伐他汀 血脂 金属蛋白酶 疗效 |
| 英文关键词:Unstableanginapectoris Rosuvastatin Blood lipid Metalloprotease Curative effect |
| 基金项目: |
|
| 摘要点击次数: 1106 |
| 全文下载次数: 1118 |
| 中文摘要: |
| 摘 要 目的：探讨瑞舒伐他汀对不稳定型心绞痛患者血脂和血浆金属蛋白酶(MMPs)的影响。方法：68例不稳定型心绞痛患者随机分为观察组和对照组各34例。对照组予抗凝、扩血管、降脂和改善心肌微循环等综合性对症支持治疗；观察组在此基础上加用瑞舒伐他汀片10 mg，po qd，连用6个月。观察两组血脂（TC、TG、LDL-C、HDL-）和血浆MMP-2和MMP-8水平变化。比较两组临床总有效率。结果：观察组患者TC、TG和LDL-C水平均较前明显下降，HDL-C水平较前明显上升(P<0.05)，对照组血脂各指标治疗前后无明显变化(P>0.05)；治疗后两组血浆MMP-2和MMP-8水平较治疗前明显下降(P<0.05或0.01)，且观察组下降幅度更显著(P<0.05)。观察组临床总有效率明显优于对照组(P<0.05)，治疗期间两组均未出现明显不良反应。结论：阿瑞舒伐他汀治疗不稳定型心绞痛具有较好的疗效，安全性较好，能明显降低血脂和血浆MMP-2和MMP-8水平，有利于动脉粥样硬化斑块的稳定，具有良好的心血管保护作用。 |
| 英文摘要: |
| ABSTRACT Objective:To explore the effect of rosuvastatin tablets on the plasma levels of lipid and metalloprotease in the treatment of patients with unstable anginapectoris (UAP).Methods:68 patients with UAP were randomly divided into the observation group(34 cases) and controlled group(34 cases). All the patients got comprehensive traditional supportive treatments as anti freezing, vessel dilation, lipid reduction, and myocardium microcirculation improving. The patients in the observation group got an extra treatment by taking rosuvastatin tablets orally 10mg, once a day for 6 months. The levels of TC、TG、LDL-C、HDL-C, MMP-2 and MMP 8 were observed. And the total effective rates of the two groups were analyzed.Results:The levels of TC、TG and LDL-C of the observation group reduced more significantly after the treatment than before it, but the level of HDL-C increased(P<0.05). The indexes of the controlled group showed no significant change after the treatment(P>0.05). The plasma levels of MMP-2 and MMP-8 of the two groups reduced more than those before the treatment (P<0.05 or P<0.01). And the change in the observation group was more obvious than that in the controlled group(P<0.05). The total clinic effective rate of the observation group was significantly higher than that of the controlled group (P<0.05), but no side effect was found in the two groups during the treatment. Conclusion: The treatment of patients with UAP with rosuvastatin could reduce the level of lipid and MMP-2 and MMP-8, play a good role in the stability of atheromatous plaque, show a good protection for cardiovascular, and therefore show effective and safe results. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
